Experimental research in the influence of the endocrine status on the antiblastic activity of cytostatics.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000315:Adrenalectomy; D000728:Androgens / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002279:Carcinoma 256, Walker / Q000188:drug therapy*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy*; D002369:Castration; D003520:Cyclophosphamide; D004967:Estrogens / Q000627:therapeutic use*; D005260:Female; D007016:Hypophysectomy; D007031:Hypothalamus / Q000293:injuries*; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D051381:Rats; D012510:Sarcoma 180 / Q000188:drug therapy*; D012513:Sarcoma, Experimental / Q000188:drug therapy*; D013963:Thyroid Hormones / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D000728:Androgens; D000970:Antineoplastic Agents; D004967:Estrogens; D013963:Thyroid Hormones; D003520:Cyclophosphamide